What it's for (Indications)
- Tiotropium + formoterol is a fixed-dose combination medication indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
- This medication is designed to provide sustained bronchodilation to improve lung function and reduce COPD exacerbations.
- It is important to emphasize that this therapy is not indicated for the relief of acute bronchospasm, nor is it intended for the primary treatment of asthma.
- Its role is strictly for ongoing management to improve the quality of life and respiratory symptoms in adults diagnosed with COPD.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical dosage involves the inhalation of a specific combination of tiotropium and formoterol, usually once or twice daily, depending on the specific inhaler device and concentration. Patients should be instructed on the correct use of the prescribed inhalation device to ensure optimal drug delivery to the lungs. It is crucial to adhere strictly to the prescribed dosing regimen and not to exceed the recommended dose, as doing so may increase the risk of adverse effects, particularly those associated with the long-acting beta2-adrenergic agonist (LABA) component. This medication is for maintenance therapy and should not be used as a rescue inhaler for sudden breathing problems. If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next dose, in which case the missed dose should be skipped. |
Safety & Warnings
Common Side Effects
- Common side effects associated with tiotropium + formoterol include, but are not limited to, dry mouth, headache, nasopharyngitis, upper respiratory tract infection, cough, pharyngitis, sinusitis, and urinary tract infection.
- Less common but more serious side effects may include paradoxical bronchospasm, which is potentially life-threatening and requires immediate discontinuation of the medication.
- Cardiovascular effects such as palpitations, tachycardia, and cardiac arrhythmias may occur due to the LABA component.
- Other potential adverse effects include blurred vision, narrow-angle glaucoma, urinary retention, hypokalemia, and hyperglycemia.
- Patients should be advised to seek immediate medical attention if they experience severe or persistent side effects, or any signs of an allergic reaction.
Serious Warnings
- Black Box Warning: **ASTHMA-RELATED DEATH:** Long-acting beta2-adrenergic agonists (LABA), such as formoterol, one of the active ingredients in tiotropium + formoterol, increase the risk of asthma-related death. Data from a large, randomized, placebo-controlled clinical trial in asthma showed that LABA increase the risk of asthma-related death. This finding with salmeterol, another LABA, is considered a class effect of LABA. The safety and effectiveness of tiotropium + formoterol in patients with asthma have NOT been established. Tiotropium + formoterol is NOT indicated for the treatment of asthma. This medication should ONLY be used for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) and not for asthma or acute bronchospasm. Patients should be clearly informed of this critical distinction.
- This medication is not indicated for the relief of acute bronchospasm and should not be used as a rescue therapy.
- Acute episodes of bronchospasm should be treated with a short-acting inhaled beta2-agonist.
- Paradoxical bronchospasm, which is life-threatening, can occur and requires immediate discontinuation.
- Systemic effects of beta-agonists, such as cardiovascular effects (e.
- g.
- , tachycardia, palpitations, hypertension, prolonged QTc interval) and central nervous system stimulation (e.
- g.
- , tremor, nervousness), may occur, particularly in susceptible patients.
- Patients with cardiovascular disorders, convulsive disorders, thyrotoxicosis, or unusual responsiveness to sympathomimetic amines should use this product with caution.
- Exacerbation of COPD may occur during treatment; this medication should not be initiated in patients during rapidly deteriorating or life-threatening episodes of COPD.
- This combination is not for asthma treatment, due to an increased risk of asthma-related death with LABAs.
- Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder-neck obstruction due to the anticholinergic component.
- Hypokalemia and hyperglycemia may occur and warrant monitoring.
How it Works (Mechanism of Action)
Tiotropium + formoterol combines two distinct bronchodilators to achieve a synergistic effect. Tiotropium is a long-acting muscarinic antagonist (LAMA) that competitively and reversibly inhibits M3 muscarinic receptors in the bronchial smooth muscle. This inhibition prevents acetylcholine-induced bronchoconstriction, leading to bronchodilation. Its long duration of action is attributed to its slow dissociation from the M3 receptors. Formoterol is a long-acting beta2-adrenergic agonist (LABA) that selectively stimulates beta2-adrenergic receptors in the bronchial smooth muscle. This stimulation activates adenyl cyclase, increasing cyclic adenosine monophosphate (cAMP) levels, which in turn leads to relaxation of the bronchial smooth muscle and bronchodilation. The combined action of these two agents provides prolonged and enhanced bronchodilation, improving airflow and reducing symptoms in patients with COPD.
Commercial Brands (Alternatives)
No other brands found for this formula.